Advertisement
The Leading Source for Pharmaceutical & Biopharmaceutical Manufacturing News
Subscribe to Pharmaceutical Processing
View Sample

FREE Daily Email Newsletter

MEDA Sells NJ Facility to DPT

September 4, 2014 8:17 am | News | Comments

Meda has signed an agreement to divest the manufacturing unit in Lakewood, New Jersey, to the contract manufacturer DPT. The manufacturing facility is dedicated to global supply of the product MUSE.         

TOPICS:

Experts Meet to Advise WHO on How to Use Experimental Ebola Drugs, Vaccines

September 4, 2014 8:10 am | by Helen Branswell, The Canadian Press | News | Comments

The meeting follows on an earlier consultation during which the WHO asked ethicists and others if it would be ethical to use unlicensed Ebola drugs and vaccines in this unprecedented outbreak. The group, which met in early August, agreed that it was. Since then, much planning and research has gone into trying to prepare this group of advisers to answer questions around who should get drugs or vaccines and under what circumstances.

TOPICS:

Walgreens August Sales Increase 3.6%

September 4, 2014 8:04 am | News | Comments

Walgreens had August sales of $6.39 billion, an increase of 3.6 percent from $6.16 billion for the same month in fiscal 2013. Total front-end sales increased 2.1 percent in August compared with the same month in fiscal 2013, while comparable store front-end sales increased 1.4 percent.

TOPICS:
Advertisement

FDA: Little Evidence to Support Testosterone Drugs

September 3, 2014 3:30 pm | by MATTHEW PERRONE, AP Health Writer | News | Comments

The Food and Drug Administration says there is little evidence that testosterone-boosting drugs taken by millions of American men are beneficial, though the agency is also unconvinced by studies suggesting the hormone carries serious risks.  

TOPICS:

Google's Health Startup Forges Venture with AbbVie

September 3, 2014 3:24 pm | News | Comments

Google's ambitious health startup is teaming up with biotechnology drugmaker AbbVie in a $500 million joint venture that will try to develop new ways to treat cancer and other diseases such as Alzheimer's.        

TOPICS:

Medical Waste Cart

September 3, 2014 2:22 pm | by Nikita | Meese Orbitron Dunne Co | Product Releases | Comments

These new regulated medical waste carts meet U.S. Centers for Disease Control and Prevention (CDC) guidance for transporting hospital linens and other textiles that may be contaminated with the Ebola virus.

TOPICS:

CVS Changes Name, Stops Tobacco Sales Early

September 3, 2014 10:51 am | by TOM MURPHY, AP Business Writer | News | Comments

As CVS sharpens its focus on customer health, the nation's second-largest drugstore chain will tweak its corporate name and stop the sale of tobacco nearly a month sooner than planned. CVS Caremark said it will now be known as CVS Health, effective immediately. The signs on its roughly 7,700 drugstores won't change, so the tweak may not register with shoppers.

TOPICS:

PPD Acquires RCT Logic’s Exclusive License to Patented Clinical Trial Design Technology

September 3, 2014 10:44 am | News | Comments

PPD has acquired RCT Logic’s exclusive license from Massachusetts General Hospital for the portfolio of patents related to its sequential parallel comparison design (SPCD). SPCD is an alternative method for conducting well-controlled clinical trials that substantially decreases the impact on trial outcomes of any placebo effect.

TOPICS:
Advertisement

Zoetis Gets Conditional OK on Pig Virus Vaccine

September 3, 2014 10:33 am | by The Associated Press | News | Comments

Zoetis has received conditional approval from federal regulators for a vaccine that helps fight a virus that has killed millions of piglets since it started showing up in the United States last year. The company said that its vaccine for the porcine epidemic diarrhea virus should be available to veterinarians and pig farmers this month.

TOPICS:

Ajinomoto Althea Receives European GMP Certification

September 3, 2014 9:13 am | News | Comments

Ajinomoto Althea announced today that it has officially received its European GMP certificate issued by the MHRA. The MHRA conducted an on-site inspection on June 19, 2014 that yielded no critical or major observations. This certification provides clearance to Althea to test commercial drug product for the European market.

TOPICS:

CDC: 'Window is Closing' to Stop Ebola

September 3, 2014 9:03 am | Videos | Comments

The CDC issued a dire warning about Ebola, and CNN's Sanjay Gupta explains the challenge of containing the outbreak.                       

TOPICS:

AstraZeneca and Redx Pharma to Collaborate on Targeting Genetic Drivers of Tumor Growth

September 3, 2014 8:54 am | News | Comments

AstraZeneca has entered into a research collaboration with Redx Pharma Limited to discover and develop new molecules targeting a genetic driver of tumor growth and survival. The research will complement AstraZeneca’s strategic approach focused on genetic drivers of cancer and mechanisms of resistance to established and novel cancer therapies.

TOPICS:

British Man Released After Receiving Experimental Ebola Treatment

September 3, 2014 8:47 am | News | Comments

A British nurse infected with Ebola was discharged Wednesday from a London hospital after making a full recovery, the hospital said. William Pooley, 29, contracted the deadly disease while treating Ebola patients in Sierra Leone.    

TOPICS:

Double Mastectomy Doesn't Boost Survival for Most

September 3, 2014 8:39 am | by LINDSEY TANNER, AP Medical Writer | News | Comments

Removing both breasts to treat cancer affecting only one side doesn't boost survival chances for most women, compared with surgery that removes just the tumor, a large study suggests. The results raise concerns about riskier, potentially unnecessary operations that increasing numbers of women are choosing.

TOPICS:

UK High Court Gives Positive Judgment in Teva's Patent Case Against AstraZeneca

September 3, 2014 8:33 am | News | Comments

Teva Pharmaceutical announced that a positive judgment has been given by the UK High Court in support of Teva's case against AstraZeneca relating to the validity of EP 1,085,877 covering the SMART ( S ingle inhaler M aintenance A nd R eliever T herapy) indication for AstraZeneca's fixed dose formoterol/budesonide combination product, Symbicort®.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading